Funder: National Institutes of Health
Due Dates: January 25, 2027 (Application) | May 25, 2027 (Application) | September 25, 2027 (Application) | January 25, 2028 (Application) | May 25, 2028 (Application) | September 25, 2028 (Application) | January 25, 2029 (Application) | May 25, 2029 (Application) | September 25, 2029 (Final application)
Funding Amounts: Up to $1,400,000 in direct costs annually for five years, plus up to $120,000 annually for qualified EPPS research
Summary: Supports multi-project translational cancer research centers advancing prevention, early detection, diagnosis, and treatment toward human endpoints.
Key Information: At least one research project must include a SPORE-initiated clinical trial as a specific aim.
Description
The National Cancer Institute (NCI) supports Specialized Programs of Research Excellence through P50 Research Center Grants, with potential joint funding from the National Institute of Dental and Craniofacial Research. The program funds investigator-initiated translational research addressing an organ-specific cancer, highly related cancers, or cancers sharing activation pathways or cross-cutting themes. Research must draw on human biology using cellular, molecular, structural, biochemical, or genetic approaches.
SPOREs combine research projects, shared infrastructure, developmental research, and career enhancement to improve cancer prevention, detection, diagnosis, and treatment. Each research project must reach a translational human endpoint during the award. The program encourages collaborations that move discoveries along the translational continuum, including partnerships beyond the SPORE, and prepares new or established scientists for translational research careers.
